Subsequent to the deregulation of NF-κB and related proteins, a decrease in the expression levels of TNF-α, IL-17, and IL-23 took place, further strengthening the utilization of piclidenoson as a drug candidate to combat psoriasis. This evidence concerns the gene IL17A and psoriasis.